PROSmith & Nephew
stock1,038.00p
+17.50 (+1.71%)
Price as of 13 Oct, 14:52 · Rate limit reached. Please try again in a minute.
Good Money Guide Pro Score
Neutral
Mixed investment profile
Technical Analysis
Short-Term Outlook
Neutral
2 bull · 2 bear · 1 neutral
Medium-Term Outlook
Neutral
2 bull · 2 bear · 0 neutral
Price below 50-day MA
Price below 200-day MA
Price above 12-day EMA
Price above 26-day EMA
Neutral momentum zone
MACD above signal line
Overbought — potential reversal down
Price near upper band — potential reversal
Volatility measure — informational only
Market Statistics
Day Change
+17.50p
Exchange
LSE
Sector
Health care equipment & supplies
FCA Net Short Position
Position date: 09 Oct 2026
The aggregated net short position reported to the FCA by all position holders with positions ≥ 0.2%.
Fundamentals
Rate limit reached. Please try again in a minute.
Analyst Forecast
No overview data found
Learn about Smith & Nephew
What is Smith & Nephew?
Smith & Nephew is a global medical technology company specializing in orthopedic reconstruction, sports medicine, and advanced wound management. They develop innovative implants, surgical instruments, and dressings that help healthcare professionals improve clinical outcomes and patient mobility.
Is Smith & Nephew a good investment?
The company benefits from an aging global population that requires more orthopedic surgeries, yet it faces stiff competition and regulatory pressures that can impact profit margins. While established market leadership offers stability, investors should perform their own due diligence as this information is for educational purposes and not financial advice.
How do you invest in Smith & Nephew?
You can invest in Smith & Nephew by purchasing its shares directly through an online brokerage platform that provides access to the London Stock Exchange or the New York Stock Exchange via American Depositary Receipts (ADRs). Alternatively, you may gain exposure by investing in healthcare-focused exchange-traded funds (ETFs) that hold the stock in their portfolios.
Educational content generated by AI — not financial advice.
Time & Sales
No trades yet.
News & Sentiment
Rate limit reached. Please try again in a minute.
Community Discussion
No posts yet for SN — be the first to start the discussion.